{"id":"leuprorelin-acetate","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"10-20","effect":"Injection site reaction"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"5-15","effect":"Headache"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Bone pain (flare reaction)"},{"rate":"5-10","effect":"Gynecomastia"}]},"_chembl":{"chemblId":"CHEMBL1201199","moleculeType":"Protein","molecularWeight":"1209.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Leuprorelin works by binding to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH release (flare effect), followed by sustained suppression of these hormones through receptor desensitization. This results in profound reduction of testosterone in males and estrogen in females, making it useful for hormone-dependent cancers and certain reproductive conditions.","oneSentence":"Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:44.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Hormone receptor-positive breast cancer"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT05567198","phase":"","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-03-03","conditions":"Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)","enrollment":100},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT06169124","phase":"PHASE2","title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-08","conditions":"Adult Ovarian Granulosa Cell Tumor","enrollment":37},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT06654336","phase":"PHASE2","title":"Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)","status":"RECRUITING","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2026-03-30","conditions":"Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer","enrollment":162},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06330805","phase":"PHASE2","title":"Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-08-12","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT07444983","phase":"NA","title":"Rezvilutamide for High-Risk Prostate Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2026-02-11","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":33},{"nctId":"NCT07015268","phase":"PHASE3","title":"A Clinical Study of KLH-2109 in Patients With Endometriosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2025-06-09","conditions":"Endometriosis","enrollment":288},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":"Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":72},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":310},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":14},{"nctId":"NCT07158021","phase":"PHASE2","title":"Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-01-22","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":75},{"nctId":"NCT02274779","phase":"PHASE2","title":"Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer","status":"COMPLETED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-08-20","conditions":"Prostate Cancer","enrollment":74},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":"Breast Cancer","enrollment":181},{"nctId":"NCT05320406","phase":"PHASE2","title":"RElugolix VErsus LeUprolide Cardiac Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-06-06","conditions":"Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":94},{"nctId":"NCT06627530","phase":"PHASE4","title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2025-02-17","conditions":"Prostate Cancer","enrollment":144},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT03902951","phase":"PHASE2","title":"Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-03-17","conditions":"Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma","enrollment":28},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT06394804","phase":"PHASE2","title":"A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-29","conditions":"Low-Grade Serous Ovarian Cancer","enrollment":20},{"nctId":"NCT05701007","phase":"","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-13","conditions":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":1083},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT02772588","phase":"PHASE2","title":"AASUR in High Risk Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-05-12","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT05341115","phase":"PHASE4","title":"A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-03-14","conditions":"Central Precocious Puberty","enrollment":80},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT05122377","phase":"","title":"RWE About QOL and Compliance of Patients With OFS in China","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-03-01","conditions":"Breast Cancer, Quality of Life, Hormone Receptor-positive Breast Cancer","enrollment":562},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT06849947","phase":"PHASE2","title":"Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yeon Hee Park","startDate":"2026-02-01","conditions":"Breast Cancer Metastatic","enrollment":272},{"nctId":"NCT05873192","phase":"PHASE2","title":"Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-03","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT02960022","phase":"PHASE2","title":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-12-22","conditions":"Prostate Cancer","enrollment":900},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":"Prostatic Neoplasms","enrollment":979},{"nctId":"NCT00001481","phase":"PHASE2","title":"The Role of Hormones in Postpartum Mood Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1996-04-26","conditions":"Postpartum Depression","enrollment":74},{"nctId":"NCT03007732","phase":"PHASE2","title":"Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT","status":"COMPLETED","sponsor":"David Oh","startDate":"2017-05-17","conditions":"Prostatic Neoplasms","enrollment":23},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT07159451","phase":"PHASE2","title":"A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-10-06","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT02023463","phase":"PHASE1","title":"Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2014-04-02","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer","enrollment":25},{"nctId":"NCT03519178","phase":"PHASE1, PHASE2","title":"A Study of PF-06873600 in People With Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-03-07","conditions":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","enrollment":155},{"nctId":"NCT05669664","phase":"PHASE2","title":"Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-20","conditions":"Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma","enrollment":21},{"nctId":"NCT03555578","phase":"","title":"Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg \"All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)\"","status":"RECRUITING","sponsor":"Takeda","startDate":"2017-11-02","conditions":"Spinal and Bulbar Muscular Atrophy","enrollment":1890},{"nctId":"NCT05896293","phase":"PHASE2","title":"Kisspeptin Administration Subcutaneously to Patients With IHH","status":"RECRUITING","sponsor":"Stephanie B. Seminara, MD","startDate":"2023-02-03","conditions":"Hypogonadotropic Hypogonadism","enrollment":36},{"nctId":"NCT06449027","phase":"PHASE3","title":"Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-08-21","conditions":"Breast Cancer Subjects","enrollment":211},{"nctId":"NCT07187947","phase":"","title":"Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-18","conditions":"Gender Incongruence, Cardiovascular (CV) Risk, Cardiovascular Disease Risk Factor","enrollment":500},{"nctId":"NCT06348264","phase":"PHASE2","title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-10-10","conditions":"Salivary Gland Neoplasm Duct","enrollment":37},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT06512207","phase":"NA","title":"A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer","status":"RECRUITING","sponsor":"Jinzhou Medical University","startDate":"2023-12-03","conditions":"NSCLC, Stage III, NSCLC, Stage IV","enrollment":80},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT07134920","phase":"","title":"Norethindrone Impact on Receptiva Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inception Fertility Research Institute, LLC","startDate":"2025-08-12","conditions":"Infertility (IVF Patients), Infertility Female","enrollment":700},{"nctId":"NCT05625087","phase":"PHASE2","title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2023-10-19","conditions":"Breast Cancer Stage IV","enrollment":162},{"nctId":"NCT05605964","phase":"PHASE3","title":"Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2023-01-25","conditions":"Prostate Cancer","enrollment":387},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT03298087","phase":"PHASE2","title":"Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-07-01","conditions":"Newly Diagnosed Oligometastatic Prostate Cancer","enrollment":28},{"nctId":"NCT03649724","phase":"PHASE2","title":"The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-11-27","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":180},{"nctId":"NCT04181203","phase":"PHASE3","title":"Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-01-09","conditions":"Prostate Cancer","enrollment":490},{"nctId":"NCT02319837","phase":"PHASE3","title":"Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2014-12-17","conditions":"Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate","enrollment":1068},{"nctId":"NCT04249154","phase":"PHASE2","title":"Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2019-09-03","conditions":"Prostate Cancer","enrollment":77},{"nctId":"NCT02903368","phase":"PHASE2","title":"Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-10-19","conditions":"Prostate Cancer","enrollment":118},{"nctId":"NCT04194554","phase":"PHASE1, PHASE2","title":"A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-11-06","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT05333328","phase":"PHASE4","title":"OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk","status":"RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2023-02-06","conditions":"Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer","enrollment":418},{"nctId":"NCT02278185","phase":"PHASE2","title":"Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-11-11","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer","enrollment":19},{"nctId":"NCT00544830","phase":"PHASE2","title":"Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2006-07-18","conditions":"PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":29},{"nctId":"NCT03703778","phase":"","title":"Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2016-05-22","conditions":"Prostate Cancer","enrollment":300},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":"Prostate Adenocarcinoma","enrollment":25},{"nctId":"NCT06225284","phase":"PHASE2","title":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-08-22","conditions":"Triple Negative Breast Cancer, Premenopausal Breast Cancer","enrollment":124},{"nctId":"NCT03951831","phase":"PHASE2","title":"REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mark Stein","startDate":"2019-05-16","conditions":"Prostate Cancer Metastatic","enrollment":26},{"nctId":"NCT06926933","phase":"PHASE4","title":"Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty","status":"RECRUITING","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2024-12-12","conditions":"CPP","enrollment":50},{"nctId":"NCT04302454","phase":"PHASE3","title":"Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2020-03-19","conditions":"Prostate Cancer","enrollment":280},{"nctId":"NCT02346253","phase":"NA","title":"High-Dose Brachytherapy in Treating Patients With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2015-01-13","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":146},{"nctId":"NCT00687739","phase":"PHASE3","title":"Prevention of Obesity in Women Via Estradiol Regulation","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-05","conditions":"Obesity","enrollment":79},{"nctId":"NCT05440383","phase":"PHASE3","title":"A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2022-10-11","conditions":"Uterine Fibroids (MeSH Heading: Leiomyoma)","enrollment":287},{"nctId":"NCT06855589","phase":"PHASE3","title":"Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.","status":"NOT_YET_RECRUITING","sponsor":"Charles LeMoyne Hospital","startDate":"2025-03","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":400},{"nctId":"NCT04445025","phase":"EARLY_PHASE1","title":"Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis","status":"COMPLETED","sponsor":"Colorado Center for Reproductive Medicine","startDate":"2020-09-01","conditions":"Infertility, Endometriosis","enrollment":30},{"nctId":"NCT06145438","phase":"PHASE3","title":"Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery","status":"COMPLETED","sponsor":"Universitas Diponegoro","startDate":"2023-09-04","conditions":"Endometriosis Ovary","enrollment":80},{"nctId":"NCT02588404","phase":"","title":"The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient","status":"WITHDRAWN","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT04992026","phase":"PHASE2","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-01-01","conditions":"Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone","enrollment":130},{"nctId":"NCT02685397","phase":"PHASE2, PHASE3","title":"Management of Castration-Resistant Prostate Cancer with Oligometastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2016-10","conditions":"Castration-resistant Prostate Cancer Patients with Oligometastases","enrollment":102},{"nctId":"NCT03035032","phase":"PHASE4","title":"A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2017-06-23","conditions":"Prostate Cancer","enrollment":107},{"nctId":"NCT02366494","phase":"","title":"Micro RNAs to Predict Response to Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-04-29","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT03990194","phase":"","title":"Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer","status":"WITHDRAWN","sponsor":"RECORDATI GROUP","startDate":"2020-03-01","conditions":"Prostate Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":66,"reaction":"FATIGUE"},{"count":47,"reaction":"NAUSEA"},{"count":44,"reaction":"PROSTATE CANCER"},{"count":43,"reaction":"ANAEMIA"},{"count":38,"reaction":"ASTHENIA"},{"count":38,"reaction":"DEATH"},{"count":38,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":35,"reaction":"OFF LABEL USE"},{"count":32,"reaction":"PROSTATIC SPECIFIC ANTIGEN INCREASED"},{"count":30,"reaction":"DIARRHOEA"}],"_approvalHistory":[],"publicationCount":306,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Leuplin","Leuplin PRO for Injection Kit 22.5 mg","Leuplin SR for Injection Kit 11.25 mg","Prostap® SR","Leuplin SR 11.25 mg Injection Kit"],"phase":"phase_3","status":"active","brandName":"Leuprorelin acetate","genericName":"Leuprorelin acetate","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Leuprorelin acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased sex hormone production. Used for Advanced prostate cancer, Hormone receptor-positive breast cancer, Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}